What is Orion Genomics?
Orion Genomics operates at the intersection of advanced molecular science and industrial application. By leveraging a robust portfolio of over 100 patents, the organization provides critical technological support through its Genomics Research and Service Division and a CLIA-Certified clinical laboratory. Beyond its core research capabilities, the company maintains a significant footprint in Southeast Asia via its subsidiary, Orion Biosains. This division is specifically tasked with optimizing the oil palm industry through technical expertise and strategic partnerships, effectively bridging the gap between complex genomic data and tangible improvements in global food production and energy resource management.
How much funding has Orion Genomics raised?
Orion Genomics has raised a total of $479K across 2 funding rounds:
Debt
$150K
Debt
$329K
Debt (2020): $150K with participation from PPP
Debt (2021): $329K led by PPP
Key Investors in Orion Genomics
PPP
Public-Private Partnership
What's next for Orion Genomics?
With the recent infusion of capital, Orion Genomics is well-positioned to accelerate its research and development initiatives while expanding its operational reach. The company is expected to prioritize the commercialization of its diagnostic services and deepen its penetration into the agricultural biotechnology market. By focusing on sustainable yield improvements and precision healthcare, Orion Genomics aims to leverage its current financial stability to transition from a research-heavy entity into a dominant, vertically integrated leader in the global genomics landscape. Future strategic moves will likely involve scaling its clinical laboratory infrastructure and enhancing its proprietary technology stack to meet the rising demand for data-driven agricultural solutions.
See full Orion Genomics company page
